News | July 17, 2024
Lupin divests US commercial women's health specialty business to Evofem
Lupin can receive a potential total consideration of up to USD 84 million based on future contingent milestones
Lupin can receive a potential total consideration of up to USD 84 million based on future contingent milestones
The company is planning to expand its plant capacity in in Vapi
Directs officials to ensure that challenges hampering their effective implementation are resolved early in coordination with states
Acquisition to expand Lilly's immunology pipeline with oral integrin therapies
The My Green Lab Certification is the gold standard for laboratory sustainability practices worldwide
Dr. Roopal Thakkar joined Abbott/AbbVie in 2003 as part of the Physician Development Program
Acquisition provides Ligand with the royalty rights to QARZIBA, a highly differentiated, commercial oncology drug marketed in 35 countries by global pharmaceutical company Recordati S.p.A.
NCIL was listed at Rs. 171 at an upper circuit premium of 90% over the fixed price band of Rs. 90
Dabur's consolidated revenue is expected to register mid to high single digit growth during Q1 FY25
Felzartamab demonstrated positive interim results from the Phase 2 IgA nephropathy (IgAN) study
Subscribe To Our Newsletter & Stay Updated
